Helix Acquisition Corp. II retains over 60% of trust account after redemptions totaling around $120M ahead of acquisition with BridgeBio Oncology Therapeutics.
On August 6, 2025, Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB) based in Boston and South San Francisco and sponsored by Cormorant Asset Management, stated that they have kept about $120 million in their trust account after redemptions by public shareholders. This amount represents more than 60% of the total cash held in trust. Additionally, TheRas, Inc. (known as BridgeBio Oncology Therapeutics) (“BBOT”), a clinical-stage biopharmaceutical company, is collaborating with Helix. BBOT focuses on advancing a new pipeline of innovative small molecule therapeutics for RAS and PI3Kα malignancies. The deadline for redemption requests was set for July 31, 2025.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments